Vanguard Capital Management
CADL icon

Vanguard Capital Management’s Candel Therapeutics CADL Stock Holding History

Vanguard Capital Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Buy
2,694,040
+231,283
+9% +$1.75M ﹤0.01% 2277
2026
Q1 		$12.1M Buy
+2,462,757
New +$13.4M ﹤0.01% 2626

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Vanguard Capital Management's CADL Position: Q2 2026 in Review

Vanguard Capital Management increased its Candel Therapeutics (CADL) stake by 9.4% in Q2 2026, buying an estimated $1.75M and bringing the position to 2,694,040 shares worth $27.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Vanguard Capital Management first reported a position in CADL in Q1 2026 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Vanguard Capital Management held 2,694,040 shares of Candel Therapeutics worth $27.7M as of Q2 2026.
  • Vanguard Capital Management bought 231,283 Candel Therapeutics shares in Q2 2026, an estimated $1.75M.
  • Candel Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2277 holding.
  • Vanguard Capital Management first reported a position in Candel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.